



## Review Article

## Open Access

## Developments in Cardiovascular Proteomics

Melissa A Noronha<sup>1</sup>, Christopher Linden<sup>2</sup> and Parveen Sharma<sup>2\*</sup><sup>1</sup>Children's Hospital of Michigan, 3901 Beaubien St. Detroit, Michigan 48201, USA<sup>2</sup>MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L69 3GE, UK**Abstract**

Cardiovascular diseases (CVD) are the leading cause of mortality and morbidity worldwide. These diseases can occur rapidly as seen in acute myocardial infarction or develop over a number of years as seen in chronic heart failure. The use of a number of drugs for chronic conditions in our aging population is compounding existing rates of CVDs due to cardiotoxicity. Recent advances in proteomics coupled with innovative separation and isolation techniques of subproteomes have vastly improved our knowledge of the cardiac proteome. Mass spectrometry imaging (MSI) is further providing information on spatial distribution of proteins and drugs. Here, we evaluate current advances in separation and detection of proteins, drugs and active metabolites being used to gain insights into mechanisms and diagnostic markers. Taken together these innovative techniques provide the necessary tools to investigate a system biology approach into cardiac disease and toxicity.

**Keywords:** Cardiac; Disease; Cardiotoxicity; Sub-proteome; Mass spectrometry imaging

**Introduction**

Cardiovascular disease (CVD) is the leading cause of global morbidity and mortality, causing approximately 30% of all deaths in the United States [1] and the UK [2]. The on and off-target cardiovascular system (CVS) effects of a multitude of drugs for different of conditions; including beta blocking agents, chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) [3-5] and anti-cancer agents add to the burden [6,7]. As the treatments for acute complications of CVD continue to improve, the epidemiology of CVD in our aging population is rapidly evolving from acute conditions to chronic disease.

An in-depth understanding of both the healthy and distressed CVS will allow greater understanding of the processes and mechanisms that may go awry in CVD. Many recent studies have used transcriptome and RNA profiling to describe CVD processes [8-10] and search for biomarkers of disease [11,12]. While these studies have shown vital aspects of molecular changes in CVD it is essential to understand the impact disease has at a protein level. Studies have shown in humans that not only do differences exist between DNA and the final mRNA product [13,14], but there is also marked variation in the expected proteome [15]. Consequently, a thorough understanding of the cardiovascular proteome is crucial to elucidating disease progression, biomarkers and potential therapeutic targets of CVD. Complicating things further, numerous studies point at post-translational modifications that not only regulate key processes in the CVS [16-18] but are also responsible for CVD pathologies and progression [19]. Recent innovative techniques using novel proteomic technologies to enrich and separate sub-proteomes have advanced our knowledge of disease progression and enhanced our ability to identify markers of disease and targets for new therapeutic strategies.

**Gel based proteomics**

Early examination of cardiac proteins were extensively carried out using two-dimensional gel electrophoresis (2DE) techniques and although these techniques have been predominantly replaced by gel-free methods, key studies still employ this well-established system [20]. In this technique, homogenized samples of cardiac tissue are solubilized and denatured, then separated based on isoelectric point and molecular mass using sodium dodecyl sulphate-polyacrylamide

gel electrophoresis (SDS-PAGE) [21]. In this technique, which offers a method to reduce the complexity of the entire sample, protein bands or spots are excised out of the gel and further analyzed by tandem mass spectrometry. This approach has led to fundamental advances in healthy cardiac proteomics [22,23], stem cell derived cardiac maturation [24], in-depth organellar proteomes [25,26] as well as changes that occur upon disease [23,27-30] and those that are induced by drugs [31]. In particular this technique provides a simple method of detecting post-translational modifications such as acetylation, glycosylation, phosphorylation and deamidation, in which there has been a shift in molecular weight and isoelectric points of the protein [20]. Methods utilizing 2DE do however tend to be biased against proteins with hydrophobic regions such as membrane proteins and biased towards high abundance proteins. 2DE also has a limited dynamic range of  $10^4$  magnitude [32,33] compared with the very high dynamic range of protein abundance, estimated at  $10^6$  for cells and tissues [32] and  $10^{12}$  for plasma [23,32,34]. In an effort to overcome these biases, new separation methodologies as well as advancements in mass spectrometry instrument technologies have reduced the need for separating proteins using a gel based system (Figure 1).

**In-depth analysis of the cardiac sub-proteomes**


In an effort to analyze the cardiac sub-proteomes and in-turn reduce the complexities of the samples, several subcellular fractionation methods exist which first fractionate the samples. These methods include differential centrifugation, flow cytometry, immune-based isolation, membrane protein enrichment strategies and/or density gradient isolation of organelles. These techniques have been applied to study the sub-proteomes of cardiac sarcomeric enriched fractions [35], myofilaments [36,37], mitochondria [38-41] and nuclei [41,42].

**\*Corresponding author:** Parveen Sharma, Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, Institute of Translational Medicine, University of Liverpool, Sherrington Building, Liverpool, L69 3GE, UK, Tel: 0151 7950149; E-mail: [parveen.sharma@liverpool.ac.uk](mailto:parveen.sharma@liverpool.ac.uk)

Received April 14, 2016; Accepted May 12, 2016; Published May 18, 2016

**Citation:** Noronha MA, Linden C, Sharma P (2016) Developments in Cardiovascular Proteomics. J Proteomics Bioinform 9: 144-150. doi:10.4172/jpb.1000400

**Copyright:** © 2016 Noronha MA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



**Figure 1: Schematic of mass spectrometry workflow.** Separation based on 2D gel electrophoresis and current organelle and post-translational modification separation have helped improve mass spectrometry analysis. Mass spectrometry imaging further is providing spatial distribution information of proteins and drugs with tissue sections.

One key sub-proteome however that often gets overlooked is cell-surface proteins. These proteins are difficult to isolate and enrich due to their low abundance and relatively low solubility in aqueous media. This challenge has prompted us and others to develop and modify cell surface enrichment methodologies that can be coupled to mass spectrometry techniques to identify existing and novel proteins in this key cellular compartment.

### Cell surface proteomics

The cardiomyocyte plasma membrane is essential to the function of the heart, from the spread of an action potential to the regulation of inotropic and chronotropic changes of the heart. Analyzing cardiac membrane proteins is crucial to a better understanding of heart function especially when we consider that the majority of cardiac disorders including arrhythmias, cardiomyopathies and conduction defects can be attributed to altered expression, function, or subcellular localisation of cardiac ion channels and associated membrane proteins [43-46]. Thus the identification and characterization of membrane proteins is paramount to the understanding of cardiac dysfunction and the search for therapeutic targets. With this in mind, several techniques have been developed recently to isolate and purify plasma membrane proteins including: colloidal bead isolation, biotinylation and glyco-capture, each having its own advantages and limitations which will be discussed in turn.

**Colloidal silica bead membrane isolation:** The silica bead plasma membrane isolation procedure uses positively charged colloidal silica beads to coat and bind to the anionic plasma membrane, and following homogenization and centrifugation, the plasma membrane is stripped from the rest of the cell [47] and then further purified in a discontinuous

nycodenz gradient. Recently we refined this protocol in order to couple it with shot-gun proteomics [48] and used it to identify plasma membrane proteins *in vivo* [49] and *in vitro* [50]. Our *in vitro* analysis of the mouse and human cardiomyocytes identified a total of 3033 mouse and 2762 cardiac proteins. This study method identified a total of 555 membrane associated proteins which included Tmem65, a novel cardiac membrane protein shown to regulate essential cardiomyocyte functionality [50]. This isolation procedure is however limited by its tendency to rupture cells, especially cells in early developmental stages which may have a dynamic membrane due to morphological immaturity and cause them to leak. This allows the beads to enter the cell and bind to internal organelle membranes thereby significantly contaminating the plasma membrane fraction [47,51].

**Biotinylation:** Biotinylation is used to isolate cell surface proteins by exploiting the strong affinity of biotin for avidin. Preparations of cell-impermeable, modified biotin allow it to bind to primary amines of exposed proteins in a cell culture system or using the *in vivo* application those accessible via the blood stream [52,53]. The proteins can then be isolated with avidin beads and following elution from the biotin-avidin complex these proteins can be identified using mass spectrometry [53]. We have previously utilized this technique to identify cell surface markers on lineage specific stem cells, isolated from mouse embryos [54] which results in their complete separation using fluorescence assisted cell sorting (FACS). More recently, Strassberger et al. [55] used biotinylation combined with mass spectrometry to extract differentially expressed cell surface proteins in myeloid leukemia cell lines compared to normal human granulocytes. They identified a number of proteins found preferentially in myeloid leukemia cells and were able to target one of them, namely CD166/ALCAM, to kill these cells *in vitro*. This

methodology is limited however in its ability to extract cell membrane proteins without an exposed extracellular domain thereby biasing against membrane proteins that are associated with the intracellular face of the plasma membrane and proteins fully enveloped inside the phospholipid bilayer.

**Glycosylation:** Glycosylation is the most common post-translational modification [56] and aberrant glycosylation has been shown to be early indicator of cellular changes in a multitude of human diseases including cancer, inflammation and neurodegeneration [57-59]. Alterations in plasma membrane glycoproteins have also been reported in ischemia reperfusion injuries [60] and cardiac hypertrophy [61]. Most membrane-bound and secretory proteins synthesized by mammalian cells are glycosylated and thereby may provide useful diagnostic tools as proteins that are shed from the cell surface during disease as well as offer mechanistic insights into disease progression and pathology. This understanding has thereby stemmed a wide variety of techniques to specifically isolate cell surface and plasma secreted glycoproteins. These include separation based on hydrophilic interactions [60,62,63], exploiting the high affinity of glycosylated proteins and peptides for lectins and the chemical capture of glycoproteins using hydrazide technology. A variety of lectins are available that selectively bind to different oligosaccharide epitopes and thereby can specifically isolate for a unique sub-set of glycoproteins containing a specific glycan moiety [59]. Although no one lectin is capable of isolating a cell's complete glycoprotein complement, studies are now combining multiple lectins to achieve greater coverage [59].

Hydrazide technology aims to isolate a broader range of glycoproteins. This procedure involves oxidizing carbohydrates, to convert cis-diol groups into aldehydes so that they may be linked to hydrazide groups on solid supports, leading to their enrichment [56]. This technique was further refined for use in live cells by Wollscheid et al. [64] who showed that the gentle biocytin hydrazide labelling of oxidized carbohydrates is cell impermeable and can therefore be used to characterize changes in the cell surface glycoproteome. This procedure, termed cell surface capture (CSC), has recently been used to establish a cell surface protein atlas (CSPA) in which researchers have used CSC technology to isolate surface proteins from 41 human and 31 mouse cell types providing an invaluable cell surface resource [65]. A study conducted by Parker et al. [60] used multiple methods to enrich for glycoproteins in myocardial ischemia and reperfusion injury and identified extracellular and cell surface proteins involved in the various stages of cardiac remodeling. Their study suggested that cardiac remodeling following myocardial ischemia may begin much earlier than originally hypothesized. In a more recent study Yang et al. [66] identified 32 glycosite containing peptides elevated in a canine model of dyssynchronous heart failure of which 13 glycopeptides were reverted to normal levels after cardiac resynchronization therapy [66]. The major drawback of hydrazide based techniques is that efficient detection of glycosylated proteins requires the removal of the oligosaccharide moieties from the glycoprotein [67]. For N-glycosylation the  $\beta$ -aspartylglycosylamine linkage can be selectively cleaved using peptide-N-glycosidase F (PNGaseF) but until recent developments those moieties in which the root  $\beta$ -1,4-acetylglucosamine had been fucosylated were missed in the analysis [68]. Recent protocols however, have used *Lens culinaris* Agglutinin (LCA) to enrich for core fucosylated (CF) proteins, followed by Endo F3 partial deglycosylation and NanoLC-MS/MS. This identified CF proteins in human serum from healthy volunteers and patients with pancreatic cancer [69] and hepatocarcinoma [70]. This technique provides an essential tool to ensure greater coverage of the glycoproteome and indeed Parker

et al. [60] demonstrated that a combination of techniques to enrich for glycoproteins offers greater depth. O-linked glycosylation further lacks a common moiety, leaving its cleavage more challenging and to date a cocktail of glycosidases have been used [68]. A lack of consensus currently limits their detection and thus the majority of studies have focused on N-linked glycoprotein analysis [59].

## Phosphoproteomics

When discussing cardiac sub-proteomes it is hard to ignore the phosphoproteome. Reversible protein phosphorylation is not only vital for the normal coordinated function of the heart but is also implicated in disease initiation and progression. This post-translational modification is essential for propagating cell signaling events in response to hormones, second messengers and pharmacological agents.

Several methods exist to subtract phosphorylated proteins from the cellular milieu which include both in-gel and gel-free methods. Using 2D-gel electrophoresis a visual migration of the protein can be monitored due to additional charge of the phosphorylated group which can then be specifically excised from the gel, purified and then identified by mass spectrometry methods. A recent study using 2D-gel electrophoresis identified 22 proteins with significantly changed phosphorylation states expressed during the acute off-target cardiotoxic effects of the chemotherapeutic agent doxorubicin. This study highlighted key signaling pathways involved in energy metabolism, sarcomeric function/structure and chaperone activity which could lead to identification of the early events involved in cardiotoxicity [71].

As previously mentioned, there has been a deviation from gel based methods and gel-free methods are predominantly used for phosphoprotein and peptide enrichment which include the use of titanium dioxide beads and immobilized metal affinity chromatography (IMAC) combined with mass spectrometry [72]. Titanium dioxide has a very high affinity for phosphopeptides and has been shown to be able to isolate femtomoles of phosphopeptides from complex protein mixtures [73,74]. Prior to the identification of proteins and signaling pathways involved in disease processes, it is essential to assess the healthy state. Lundby et al. [75] used titanium dioxide phospho-enrichment coupled to LC-MS/MS, to quantify the changes in the mouse cardiomyocyte phosphoproteome *in vivo* upon acute beta1-adrenergic and beta2-adrenergic stimulation. They uncovered 670 phosphorylation sites regulated by beta1-adrenergic stimulation which included previously unknown modifications of channels and transporters affecting cardiac function, highlighting the utility of phosphoproteomics analysis for elucidating cardiac signaling networks [75,76]. Wijeratne et al. [77] describe a novel workflow involving reductive alkylation by acetone to label peptides in tandem with titanium dioxide isolation followed by mass spectrometry based identification to effectively quantify phosphorylative changes in a mouse model of ischemia-reperfusion injury. Using this methodology they found increased cardioprotection in a mouse model of ischemia-reperfusion injury was due to low molecular weight fibroblast growth factor-2 (LMW FGF2) mediated phosphorylation of key downstream signaling pathways [77].

## Quantification

Although an in-depth review of protein and peptide quantification is outside the scope of this review they have been reviewed extensively elsewhere [23,78-80]. The most commonly used techniques for peptide quantification used in mass spectrometry can be divided into those that offer a relative quantification between healthy and diseased/treated samples and those that offer absolute quantification. Label

free relative quantification techniques include spectral counting, peak intensity comparisons and more recently SWATH analysis [50,79,81-83] whereas labelled techniques include SILAC, iTRAQ, enzymatic  $^{18}\text{O}$  labelling and *in vivo*  $^2\text{H}_2\text{O}$  labelling [79,84-87]. Absolute techniques incorporate the use of internally spiked absolute quantification (AQUA) peptides to quantify absolute amounts using MRM, SRM, iTRAQ [88-91]. These techniques have been extensively used in cardiovascular proteomics [23,78,80] and can be combined with a number of the sub-proteome separation techniques in which quantification of differentially expressed proteins are informative about mechanism of disease progression, pathway analysis of potential drug targets and biomarkers. For example, the quantitative accuracy of SWATH analysis has been compared to that of SRM analysis [92] and has the ability to reproducibly identify low abundance proteins from small numbers of cells (50 000 cells) and from small amounts of tissue from biopsy samples (0.2-0.5 mg) including cardiac tissue [92]. SWATH and SRM were used in combination with CSC glycoprotein enrichment methods to provide quantitative and qualitative expression of 78 human and mouse tissue cell surface proteins [65]. Lau et al. combined *in vivo*  $^2\text{H}_2\text{O}$  labelling of drinking water with subcellular fractionation to quantitate protein dynamics and turnover in healthy mice and those with cardiac hypertrophy. This invaluable resource of cardiac disease progression provides quantification of the *in vivo* half-lives of 3,228 proteins and the expression of 8,064 proteins under healthy and diseased states [86]. Lam et al. [93] combined differential centrifugation to isolate mitochondria from human and mouse hearts with  $\text{TiO}_2$  purification of phosphoproteins with MRM quantification to establish 176 MRM transitions specific to protein modifications. These transitions can now be used to quantify alterations in the level of phosphorylation under conditions of disease or pharmacological intervention.

### New mass spectrometry technologies

The advancement of mass spectrometry instrumentation and computational technologies has vastly improved the coverage and depth of the proteome. A comparison of generations of the Q Exactive instrument for example, showed that the latest iteration of the Q Exactive HF has the capability to detect > 4000 proteins in a 1 hour gradient from 1  $\mu\text{g}$  of Hela cells prior to any fractionation [94]. These powerful methods offer great versatility and depth when dealing with precious samples, in particular healthy human tissues which can not only be rare and difficult to obtain but also only available in small quantities retrieved from patient biopsies. These restrictions therefore limit the amount of sample manipulation and fractionation prior to analysis. Indeed, we have used these powerful methods to identify 2754 human atrial protein groups and 2825 human ventricular protein groups from which we were then able to identify and classify chamber unique proteins without prior fractionation [95]. If however the initial sample quantity does lend itself to prior fractionation, the possibilities are extensive as demonstrated by  $\text{TiO}_2$  enrichment of phosphoproteins which when analyzed gave 7600 unique phosphopeptides in a 1 hour gradient of elution [94].

**Mass spectrometry imaging:** One limitation of sub-fractionation is the loss of spatial distribution of proteins and drugs. Emerging technologies of mass spectrometry imaging (MSI) are now providing a powerful tool that allows the analysis, detection and mapping of the biodistribution of proteins and drugs within histological sections [96]. MSI can detect endogenous and exogenous analytes including low molecular weight drugs, lipids and proteins directly from tissue samples [96] (Figure 1). This technique has traditionally been linked to MALDI ionization and accomplished by using tissue sections

mounted onto a conductive slide in water or gelatin to which one of several MALDI matrices are sprayed depending on the type of analyte to be measured [96]. The matrix then co-crystalizes with the cell components and then the region of interest is subjected to MALDI ionization for detection by mass spectrometry [96,97]. More recently MSI has evolved to use desorption electrospray ionization (DESI) [98], which overcomes complications of matrix-analyte co-crystallisation issues [99]. The technical aspects of MSI and sample preparation are beyond the scope of this review but have previously been discussed in depth [96-99]. Using these techniques Martin-Loenzo et al. [100] pinpointed specific lipids and proteins to atherosclerotic aortic mouse cardiac sections. They showed that thymosin beta 4 is differentially overexpressed in the intima layer of atherosclerotic tissue compared to media layers providing new avenues of research in the area [100]. This technique further holds a lot of promise in drug distribution analysis.

Histological sections of models of drug dosed tissue allow the detection of drug and metabolite distribution. MSI has recently been used to monitor and quantify the release of celecoxib from packaging nanoparticles delivered to the healthy and ischemic myocardium of *in vivo* models. This study identified the angiogenic potential of this drug when delivered locally to a specific region, pointing to a potential new approach for treating ischemia [101]. Drug-induced cardiotoxicity remains the major contributor to drug attrition and withdrawal from patient distribution and a major complication for off-target toxicities of a multitude of drugs [6]. Whole body MSI offers the promise to determine localization of both parent and metabolite distribution within every organ or cell type of the body early in drug development stages, potentially aiding drug testing and reducing adverse off-target reactions [96,102,103]. One major drawback of MSI is the inability to directly identify proteins and the potential need to coordinate experiments with tandem mass spectrometry methods to carry out sequence identification [104,105]. However, with the continuing development of technologies, databases are now being established by the MSI community that allows the identification of molecules directly from the mass spectrometric measurement [106]. The identification of proteins [107,108] and glycoproteins [109,110] as well as lipids and cell metabolites [106] from MSI experiments of healthy versus diseased or pharmacologically treated tissue will undoubtedly reveal deeper insights into disease mechanisms and pathways at a tissue level.

### Conclusions

This review highlights current technologies that have been developed and modified to further cardiovascular knowledge through proteomics. Taken together, these studies highlight a systems biology approach allowing the identification and quantification of potential targets, biomarkers, and mechanisms of disease progression including identification of post-translational modifications as well as methods to gain insights on the biodistribution of parent drugs and active metabolites. Applying the correct innovative techniques for a given system under healthy, diseased and drug-dosed conditions will allow us to gain further understanding into mechanisms that cause disease and drug-induced cardiotoxicity. These insights will in-turn help us to gain a deeper comprehension into cardiac disease and to reduce the number of drugs that can cause adverse cardiac reactions before they enter patient circulation.

### Acknowledgment

The authors would like to thank the MRC Centre for Drug Safety Science for support and advice on this manuscript.

## References

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, et al. (2012) Heart disease and stroke statistics-2012 update: a report from the American Heart Association. *Circulation* 125: e2-2e220.
2. Bhatnagar P, Wickramasinghe K, Williams J, Rayner M, Townsend N (2015) The epidemiology of cardiovascular disease in the UK 2014. *Heart* 101: 1182-1189.
3. Anwar A, Anwar IJ, Delafontaine P (2015) Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs. *Trends Cardiovasc Med* 25: 726-735.
4. Asghar W, Jamali F (2015) The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. *Inflammopharmacology* 23: 1-16.
5. García-Poza P, de Abajo FJ, Gil MJ, Chacón A, Bryant V, et al. (2015) Risk of ischemic stroke associated with non-steroidal anti-inflammatory drugs and paracetamol: a population-based case-control study. *J Thromb Haemost* 13: 708-718.
6. Laverty H, Benson C, Cartwright E, Cross M, Garland C, et al. (2011) How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? *British Journal of Pharmacology* 163: 675-693.
7. Maxwell CB, Jenkins AT (2011) Drug-induced heart failure. *Am J Health Syst Pharm* 68: 1791-1804.
8. Ounzain S, Micheletti R, Beckmann T, Schroen B, Alexanian M, et al. (2015) Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs. *Eur Heart J* 36: 353-368.
9. Gao C, Wang Y (2014) Transcriptome Complexity in Cardiac Development and Diseases: An Expanding Universe Between Genome and Phenome. *Circ J* 78: 1038-1047.
10. Liu Y, Morley M, Brandimarto J, Hannehalli S, Hu Y, et al. (2015) RNA-Seq identifies novel myocardial gene expression signatures of heart failure. *Genomics* 105: 83-89.
11. Pedrotty DM, Morley MP, Cappola TP (2014) Transcriptomic biomarkers of cardiovascular disease. *Prog Cardiovasc Dis* 5: 64-69.
12. Costa Ade F, Franco OL (2015) Insights into RNA transcriptome profiling of cardiac tissue in obesity and hypertension conditions. *J Cell Physiol* 230: 959-968.
13. Li M, Wang IX, Li Y, Bruzel A, Richards AL, et al. (2011) Widespread RNA and DNA sequence differences in the human transcriptome. *Science* 333: 53-58.
14. Claydon AJ, Beynon R (2012) Proteome dynamics: revisiting turnover with a global perspective. *Mol Cell Proteomics* 11: 1551-1565.
15. Lundberg E, Fagerberg L, Klevebring D, Matic I, Geiger T, et al. (2010) Defining the transcriptome and proteome in three functionally different human cell lines. *Mol Syst Biol* 6: 450.
16. Portbury AL, Ronnebaum SM, Zungu M, Patterson C, Willis MS (2012) Back to your heart: ubiquitin proteasome system-regulated signal transduction. *J Mol Cell Cardiol* 52: 526-537.
17. Darley-Usmar VM, Ball LE, Chatham JC (2014) Protein O-linked beta-N-acetylglucosamine: a novel effector of cardiomyocyte metabolism and function. *J Mol Cell Cardiol* 52: 538-549.
18. Shao D, Oka S, Brady CD, Haendeler J, Eaton P, et al. (2012) Redox modification of cell signaling in the cardiovascular system. *J Mol Cell Cardiol* 52: 550-558.
19. Murphy E, Kohr M, Sun J, Nguyen T, Steenbergen C (2012) S-nitrosylation: a radical way to protect the heart. *J Mol Cell Cardiol* 52: 568-577.
20. Rogowska-Wrzęsinska A, Le Bihan MC, Thaysen-Andersen M, Roepstorff P (2013) 2D gels still have a niche in proteomics. *J Proteomics* 88: 4-13.
21. Gianazza E, Osio L, Grazioli G, Astrua-Testori S, Righetti PG, et al. (1987) An examination of heart proteins by two-dimensional electrophoresis. *Clin Chem* 33: 2011-2018.
22. Scholten A, Heck AR (2013) Determining Protein Concentrations of the Human Ventricular Proteome. In: Vivanco F (Ed) *Heart Proteomics*, Humana Press.
23. Sharma P, Cosme J, Gramolini AO (2013) Recent advances in cardiovascular proteomics. *J Proteomics* 81: 3-14.
24. Poon E, Keung W, Liang Y, Ramalingam R, Yan B, et al. (2015) Proteomic Analysis of Human Pluripotent Stem Cell-Derived, Fetal, and Adult Ventricular Cardiomyocytes Reveals Pathways Crucial for Cardiac Metabolism and Maturation. *Circ Cardiovasc Genet* 8: 427-436.
25. Giorgianni F, Koirala D, Weber KT, Beranova-Giorgianni S (2014) Proteome Analysis of Subsarcolemmal Cardiomyocyte Mitochondria: A Comparison of Different Analytical Platforms. *Int J Mol Sci* 1: 9285-9301.
26. Kim TY, Wang D, Kim AK, Lau E, Lin AJ, et al. (2012) Metabolic labeling reveals proteome dynamics of mouse mitochondria. *Mol Cell Proteomics* 11: 1586-1594.
27. Didangelos A, Yin X, Mandal K, Saje A, Smith A, et al. (2011) Extracellular matrix composition and remodeling in human abdominal aortic aneurysms: a proteomics approach. *Mol Cell Proteomics* 10: M111.
28. Dietl A, Winkel I, Deutzmann R, Schröder J, Hupf J, et al. (2014) Interatrial differences of basal molecular set-up and changes in tachycardia-induced heart failure—a proteomic profiling study. *Eur J Heart Fail* 16: 835-845.
29. Shekar KC, Li L, Dabkowski ER, Xu W, Ribeiro RF Jr, et al. (2014) Cardiac mitochondrial proteome dynamics with heavy water reveals stable rate of mitochondrial protein synthesis in heart failure despite decline in mitochondrial oxidative capacity. *J Mol Cell Cardiol* 7: 88-97.
30. Manakov D, Ujickova H, Pravenec M, Novotny J4 (2016) Alterations in the cardiac proteome of the spontaneously hypertensive rat induced by transgenic expression of CD36. *J Proteomics*.
31. Yin X, Dwyer J, Langley SR, Mayr U, Xing Q, et al. (2013) Effects of perhexiline-induced fuel switch on the cardiac proteome and metabolome. *J Mol Cell Cardiol* 55: 27-30.
32. McGregor E, Dunn MJ (2006) Proteomics of the heart: unraveling disease. *Circ Res* 98: 309-321.
33. Rabilloud T (2002) Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. *Proteomics* 2: 3-10.
34. Anderson NL, Anderson NG, Pearson TW, Borchers CH, Paulovich AG, et al. (2009) A human proteome detection and quantitation project. *Mol Cell Proteomics* 8: 883-886.
35. Warren CM, Geenen DL, Helseth DL Jr, Xu H, Solaro RJ (2010) Sub-proteomic fractionation, iTRAQ, and OFFGEL-LC-MS/MS approaches to cardiac proteomics. *J Proteomics* 73: 1551-1561.
36. Yin X, Cuello F, Mayr U, Hao Z, Hornshaw M, et al. (2010) Proteomics Analysis of the Cardiac Myofibrillar Subproteome Reveals Dynamic Alterations in Phosphatase Subunit Distribution. *Mol Cell Proteomics* 9: 497-509.
37. Fert-Bober J, Giles JT, Holewinski RJ, Kirk JA, Uhrigshardt H, et al. (2015) Citrullination of myofibrillar proteins in heart failure. *Cardiovasc Res* 108: 232-242.
38. Taylor SW, Fahy E, Zhang B, Glenn GM, Warnock DE, et al. (2003) Characterization of the human heart mitochondrial proteome. *Nat Biotechnol* 21: 281-286.
39. Elstner M, Andreoli C, Ahting U, Tetko I, Klopstock T, et al. (2008) MitoP2: an integrative tool for the analysis of the mitochondrial proteome. *Mol Biotechnol* 40: 306-315.
40. Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, et al. (2008) A Mitochondrial Protein Compendium Elucidates Complex I Disease Biology. *Cell* 13: 112-123.
41. Kislinger T, Cox B, Kannan A, Chung C, Hu P, et al. (2006) Global survey of organ and organelle protein expression in mouse: combined proteomic and transcriptomic profiling. *Cell* 12: 173-186.
42. Murray CI, Barrett M, Van Eyk JE (2009) Assessment of ProteoExtract subcellular fractionation kit reveals limited and incomplete enrichment of nuclear subproteome from frozen liver and heart tissue. *Proteomics* 9: 3934-3938.
43. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, et al. (1998) Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. *Nature* 39: 293-296.
44. Sanguinetti MC, Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. *Nature* 440: 463-469.
45. Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, et al. (2005) Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. *Proc Natl Acad Sci U S A* 102: 8089-8096.

46. McNair WP, Ku L, Taylor MR, Fain PR, Dao D, et al. (2004) SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. *Circulation* 110: 2163-2167.
47. Chaney LK, Jacobson BS (1983) Coating cells with colloidal silica for high yield isolation of plasma membrane sheets and identification of transmembrane proteins. *J Biol Chem* 258: 10062-10072.
48. Rast JP, Booth JWD (Eds.) *Immune Receptors*, Humana Press.
49. Cox B, Sharma P, Evangelou AI, Whiteley K, Ignatchenko V, et al. (2011) Translational Analysis of Mouse and Human Placental Protein and mRNA Reveals Distinct Molecular Pathologies in Human Preeclampsia. *Mol Cell Proteomics* 10.
50. Sharma P, Abbasi C, Lazic S, Teng AC, Wang D, et al. (2015) Evolutionarily conserved intercalated disc protein Tmem65 regulates cardiac conduction and connexin 43 function. *Nat Commun* 6: 8391.
51. Arjunan S, Reinartz M, Emde B, Zanger K, Schrader J (2009) Limitations of the colloidal silica method in mapping the endothelial plasma membrane proteome of the mouse heart. *Cell Biochem Biophys* 53: 135-143.
52. Elia G (2008) Biotinylation reagents for the study of cell surface proteins. *Proteomics* 8: 4012-4024.
53. Roesli C, Neri D, Rybak JN (2006) *In vivo* protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature. *Nat Protoc* 1: 192-199.
54. Rugg-Gunn PJ, Cox BJ, Lanner F, Sharma P, Ignatchenko V, et al. (2012) Cell-Surface Proteomics Identifies Lineage-Specific Markers of Embryo-Derived Stem Cells. *Dev Cell* 2: 887-901.
55. Strassberger V, Gutbrodt KL, Krall N, Roesli C, Takizawa H, et al. (2014) A comprehensive surface proteome analysis of myeloid leukemia cell lines for therapeutic antibody development. *J Proteomics* 99: 138-151.
56. Zhang H, Li XJ, Martin DB, Aebersold R (2003) Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. *Nat Biotechnol* 21: 660-666.
57. Dwek RA, Butters TD, Platt FM, Zitzmann N (2002) Targeting glycosylation as a therapeutic approach. *Nat Rev Drug Discov* 1: 65-75.
58. Christiansen MN, Chik J, Lee L, Anugraham M, Abrahams JL, et al. (2014) Cell surface protein glycosylation in cancer. *Proteomics* 14: 525-546.
59. Pan S, Chen R, Aebersold R, Brentnall TA (2011) Mass spectrometry based glycoproteomics--from a proteomics perspective. *Mol Cell Proteomics* 10: R110.
60. Parker BL, Palmisano G, Edwards AV, White MY, Engholm-Keller K, et al. (2011) Quantitative N-linked glycoproteomics of myocardial ischemia and reperfusion injury reveals early remodeling in the extracellular environment. *Mol Cell Proteomics* 10: M110 006833.
61. Yang S, Mishra S, Chen L, Zhou JY, Chan DW, et al. (2015) Integrated Glycoprotein Immobilization Method for Glycopeptide and Glycan Analysis of Cardiac Hypertrophy. *Anal Chem* 87: 9671-9678.
62. Takegawa Y, Deguchi K, Ito H, Keira T, Nakagawa H, et al. (2006) Simple separation of isomeric sialylated N-glycopeptides by a zwitterionic type of hydrophilic interaction chromatography. *J Sep Sci* 29: 2533-2540.
63. Di Palma S, Boersema PJ, Heck AJ, Mohammed S (2011) Zwitterionic Hydrophilic Interaction Liquid Chromatography (ZIC-HILIC and ZIC-CHILIC) Provide High Resolution Separation and Increase Sensitivity in Proteome Analysis. *Anal Chem* 83: 3440-3447.
64. Wollscheid B, Bausch-Fluck D, Henderson C, O'Brien R, Bibel M, et al. (2009) Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. *Nat Biotechnol* 27: 378-386.
65. Bausch-Fluck D, Hofmann A, Bock T, Frei AP, Cerciello F, et al. (2015) A mass spectrometric-derived cell surface protein atlas. *PLoS One* 10: e0121314.
66. Yang S, Chen L, Sun S, Shah P, Yang W, et al. (2015) Glycoproteins identified from heart failure and treatment models. *Proteomics* 15: 567-579.
67. Kaji H, Yamauchi Y, Takahashi N, Isobe T (2007) Mass spectrometric identification of N-linked glycopeptides using lectin-mediated affinity capture and glycosylation site-specific stable isotope tagging. *Nat Protoc* 1: 3019-3027.
68. Sun B, Hood L (2014) Protein-Centric N-Glycoproteomics Analysis of Membrane and Plasma Membrane Proteins. *J Proteome Res* 13: 2705-2714.
69. Tan Z, Yin H, Nie S, Lin Z, Zhu J, et al. (2015) Large-scale identification of core-fucosylated glycopeptide sites in pancreatic cancer serum using mass spectrometry. *J Proteome Res* 14: 1968-1978.
70. Yin H, Tan Z, Wu J, Zhu J, Shedden KA, et al. (2015) Mass-Selected Site-Specific Core-Fucosylation of Serum Proteins in Hepatocellular Carcinoma. *J Proteome Res* 14: 4876-4884.
71. Gratia S, Kay L, Michelland S, Sève M, Schlattner U, et al. (2012) Cardiac phosphoproteome reveals cell signaling events involved in doxorubicin cardiotoxicity. *J Proteomics* 75: 4705-4716.
72. Stensballe A, Andersen S, Jensen ON (2001) Characterization of phosphoproteins from electrophoretic gels by nanoscale Fe(III) affinity chromatography with off-line mass spectrometry analysis. *Proteomics* 1: 207-222.
73. Pinkse MW, Uitto PM, Hilhorst MJ, Ooms B, Heck AJ (2004) Selective isolation at the femtomole level of phosphopeptides from proteolytic digests using 2D-NanoLC-ESI-MS/MS and titanium oxide precolumns. *Anal Chem* 76: 3935-3943.
74. Larsen MR, Thingholm TE, Jensen ON, Roepstorff P, Jørgensen TJ (2005) Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. *Mol Cell Proteomics* 4: 873-886.
75. Lundby A, Andersen MN, Steffensen AB, Horn H, Kelstrup CD, et al. (2013) *In vivo* phosphoproteomics analysis reveals the cardiac targets of beta-adrenergic receptor signaling. *Sci Signal* 6: rs11.
76. Kuzmanov U, Emili A (2013) Using phosphoproteomics to monitor dysregulated signaling networks in cardiac disease preceding heart failure. *Bioanalysis* 5: 2863-2866.
77. Wijeratne AB, Manning JR, Schultz Jel J, Greis KD (2013) Quantitative phosphoproteomics using acetone-based Peptide labeling: method evaluation and application to a cardiac ischemia/reperfusion model. *J Proteome Res* 12: 4268-4279.
78. Mirza SP (2012) Quantitative mass spectrometry-based approaches in cardiovascular research. *Circ Cardiovasc Genet* 5: 477.
79. Meissner F, Mann M (2014) Quantitative shotgun proteomics: considerations for a high-quality workflow in immunology. *Nat Immunol* 15: 112-117.
80. Chugh S, Sharma P, Kislinger T, Gramolini AO (2012) Clinical proteomics: getting to the heart of the matter. *Circ Cardiovasc Genet* 5: 377.
81. Rosenberger G, Koh CC, Guo T, Röst HL, Kouvonen P, et al. (2014) A repository of assays to quantify 10,000 human proteins by SWATH-MS. *Sci Data* 1: 140031.
82. Bourassa S, Fournier F, Nehmé B, Kelly I, Tremblay A, et al. (2015) Evaluation of iTRAQ and SWATH-MS for the Quantification of Proteins Associated with Insulin Resistance in Human Duodenal Biopsy Samples. *PLoS One* 10: e0125934.
83. Schubert OT, Gillet LC, Collins BC, Navarro P, Rosenberger G, et al. (2015) Building high-quality assay libraries for targeted analysis of SWATH MS data. *Nat Protoc* 10: 426-441.
84. Ong SE, Mann M (2006) A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). *Nat Protoc* 1: 2650-2660.
85. Wiese S, Reidegeld KA, Meyer HE, Warscheid B (2007) Protein labeling by iTRAQ: a new tool for quantitative mass spectrometry in proteome research. *Proteomics* 7: 340-350.
86. Lau E, Cao Q, Ng DC, Bleakley BJ, Dincer TU, et al. (2016) A large dataset of protein dynamics in the mammalian heart proteome. *Sci Data* 3: 160015.
87. Castillo MJ, Reynolds KJ, Gomes A, Fenselau C, Yao X, et al. (2014) Quantitative Protein Analysis Using Enzymatic [(18)O]Water Labeling. *Current protocols in protein science. Curr Protoc Protein Sci* 76.
88. Desiere F, Deutsch EW, King NL, Nesvizhskii AI, Mallick P, et al. (2006) The PeptideAtlas project. *Nucleic Acids Res* 34: D655-658.
89. Kettenbach AN, Rush J, Gerber SA (2011) Absolute quantification of protein and post-translational modification abundance with stable isotope-labeled synthetic peptides. *Nat Protoc* 6: 175-186.

90. Picotti P, Aebersold R (2012) Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. *Nat Methods* 9: 555-566.
91. Marx V (2013) Targeted proteomics. *Nat Meth* 10: 19-22.
92. Shao S, Guo T, Koh CC, Gillessen S, et al. (2015) Minimal sample requirement for highly multiplexed protein quantification in cell lines and tissues by PCT-SWATH mass spectrometry. *Proteomics* 15: 3711-3721.
93. Lam MP, Lau E, Scruggs SB, Wang D, Kim TY, et al. (2013) Site-specific quantitative analysis of cardiac mitochondrial protein phosphorylation. *J Proteomics* 81: 15-23.
94. Kelstrup CD, Jersie-Christensen RR, Bath TS, Arrey TN, Kuehn A, et al. (2014) Rapid and deep proteomes by faster sequencing on a benchtop quadrupole ultra-high-field Orbitrap mass spectrometer. *J Proteome Res* 13: 6187-6195.
95. Lu ZQ, Sinha A, Sharma P, Kislinger T, Gramolini AO (2014) Proteomic analysis of human fetal atria and ventricle. *J Proteome Res* 13: 5869-5878.
96. Cobice DF, Goodwin RJ, Andren PE, Nilsson A, Mackay CL, et al. (2015) Future technology insight: mass spectrometry imaging as a tool in drug research and development. *Br J Pharmacol* 172: 3266-3283.
97. Parker S, Raedschelders K, Van Eyk JE (2015) Emerging proteomic technologies for elucidating context-dependent cellular signaling events: A big challenge of tiny proportions. *Proteomics* 15: 1486-1502.
98. Cooks RG, Ouyang Z, Takats Z, Wiseman JM (2006) Detection Technologies. *Ambient mass spectrometry*. *Science* 311: 1566-1570.
99. Wiseman JM, Ifa DR, Venter A, Cooks RG (2008) Ambient molecular imaging by desorption electrospray ionization mass spectrometry. *Nat Protoc* 3: 517-524.
100. Martin-Lorenzo M, Balluff B, Maroto AS, Carreira RJ, van Zeijl RJM et al. (2015) Molecular anatomy of ascending aorta in atherosclerosis by MS Imaging: Specific lipid and protein patterns reflect pathology. *Journal of Proteomics* 126: 245-251.
101. Margulis K, Neofytou EA, Beygui RE, Zare RN (2015) Celecoxib Nanoparticles for Therapeutic Angiogenesis. *ACS Nano* 9: 9416-9426.
102. Stoeckli M, Staab D, Schweitzer A, Gardiner J, Seebach D (2007) Imaging of a beta-peptide distribution in whole-body mice sections by MALDI mass spectrometry. *J Am Soc Mass Spectrom* 18: 1921-1924.
103. Goodwin RJ, Macintyre L, Watson DG, Scullion SP, Pitt AR (2010) A solvent-free matrix application method for matrix-assisted laser desorption/ionization imaging of small molecules. *Rapid Commun Mass Spectrom* 24: 1682-1686.
104. Irie M, Fujimura Y, Yamato M, Miura D, Wariishi H (2014) Integrated MALDI-MS imaging and LC-MS techniques for visualizing spatiotemporal metabolomic dynamics in a rat stroke model. *Metabolomics* 10: 473-483.
105. Shobo A, Bratkowska D, Bajinath S, Naiker S, Bester LA, et al. (2015) Visualization of Time-Dependent Distribution of Rifampicin in Rat Brain Using MALDI MSI and Quantitative LCMS/MS. *Assay Drug Dev Technol* 13: 277-284.
106. Aichler M, Walch A (2015) MALDI Imaging mass spectrometry: current frontiers and perspectives in pathology research and practice. *Lab Invest* 95: 422-431.
107. Maier SK, Hahne H, Gholami AM, Balluff B, Meding S, et al. (2013) Comprehensive identification of proteins from MALDI imaging. *Mol Cell Proteomics* 12: 2901-2910.
108. McDonnell LA, Walch A, Stoeckli M, Corthals GL (2014) MSiMass list: a public database of identifications for protein MALDI MS imaging. *J Proteome Res* 13: 1138-1142.
109. Powers TW, Neely BA, Shao Y, Tang H, Troyer DA, et al. (2014) MALDI imaging mass spectrometry profiling of N-glycans in formalin-fixed paraffin embedded clinical tissue blocks and tissue microarrays. *PLoS One* 9: e106255.
110. Jones EE, Powers TW, Neely BA, Cazares LH, Troyer DA, et al. (2014) MALDI imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma. *Proteomics* 14: 924-935.